Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER_GOV 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 HER2-positive Breast Cancer 14 Carcinoma, Non-Small-Cell Lung 5 Breast Diseases 4 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Advanced Breast Cancer 2 Stomach Neoplasms 1 Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 HER-2 Positive Colorectal Cancer 1 Estrogen Receptor-positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1

Interventions

pyrotinib 1 pertuzumab 1 Vinorelbine 1 Trastuzumab 1 Lapatinib 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2 Positive Breast Cancer × pyrotinib × Clear all

NCT06958627 2025-05-06

any

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Recruiting

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡